@avidresearch
Joined October 2009
  • Tweets34.5K
  • Following1.4K
  • Followers12.7K
1.6KMedia
Use paper tests. Not sure this is as complicated as they make it sound.
Polymarket
@Polymarket2h
JUST IN: UC Berkeley math professor stops grading homework for correctness, saying widespread AI use has made it "pointless," and now awards credit simply for turning in assignments.
1
3
630
avidresearch retweeted
Polymarket
@Polymarket2h
JUST IN: UC Berkeley math professor stops grading homework for correctness, saying widespread AI use has made it "pointless," and now awards credit simply for turning in assignments.
183
261
98
2,962
177,297
$TNGX hilarious price action to highly durable ~80% response rate in 2L PDAC.
5
1
24
4,379
avidresearch retweeted
Jeff Farley
@TradeInTheZoneOct 25
For the first time in history, nearly 60% of the S&P 500’s components are in a bear market, while the index trades 3% away from a record high.
2
5
1,161
avidresearch retweeted
Almu@almudenallyOct 26
More proof of the limited efficacy of Topo1 ADCs after a prior Topo1 #ESMO2026
2
14
1
30
5,405
Unlike the dot-com bubble, when global technology stocks surged far ahead of earnings, the current rally has been supported by stronger earnings growth. Source: @steve_donze
31
42
8
267
29,181
$PFE BD should take a good look at this
Banana Oncology
@Banana_OncologyOct 25
"mPFS: 15m"
2
16
5,963
avidresearch retweeted
Dr Amol Akhade
@SuyogCancerOct 24
Can u imagine . Not a single word or line about perioperative pembrolizumab use for presidential abstract discussion about melanoma in 2026 @myESMO . Are u amazed ? @dr_yakupergun @DrYukselUrun @OncBrothers @JacobPlieth
3
3
20
4,472
Love PRMT5. Incredible durability (better than ADCs). $TNGX will get picked up soon IMO. Room for multiple players. BeOne $BMY
Samuel Hume
@DrSamuelBHumeOct 23
Replying to @DrSamuelBHume
From the full poster, today at ESMO (BeOne Medicines).
4
5
39
6,297
avidresearch retweeted
Jordi Xiol@jordixiolOct 24
Three legit candidates for a standing ovation at the Esmo presidential this afternoon: Interpath, Volga and Dellphi
Toni Choueiri, MD
@DrChoueiriOct 24
JUST IN: DeLLphi-305: Small Cell Lung Cancer Extensive-Stage Phase III (n=563): Tarlatamab + Durvalumab vs Durvalumab as 1L maintenance after chemo-IO, to be presented by our own @sands_jacob from @DanaFarber • Median OS: 21.1 vs 12.7 months (HR 0.42) • Median PFS: 7.4 vs 1.9 months (HR 0.34) • ORR: 26.4% vs 4.1% Grade ≥3 AEs: 46.8% vs 40.6%; CRS 49.6% (most low grade). Probably new standard of care in ES-SCLC. @OncoAlert @DanaFarberNews #ESMO26
3
1
6
2,278
avidresearch retweeted
Peptime
@ItsPeptimeOct 23
GLPs killing alcoholism is one of the best side effects for society
Polymarket
@PolymarketOct 23
JUST IN: Heineken warns that the booming use of Ozempic & other weight-loss drugs threatens beer sales, as users increasingly lose their desire to drink alcohol.
9
77
5
1,224
34,816
Another interstitial lung disease death raises more deruxtecan doubts - this time with ralu-dxd plus Avastin at #ESMO26. The @ApexOnco take apexonco.com/esmo-2026-anoth…

ESMO 2026 – another death raises more deruxtecan doubts

Raludotatug deruxtecan plus Avastin has been linked with a lung disease fatality.

apexonco.com
5
3
16
8,192
avidresearch retweeted
Jacob Plieth@JacobPliethOct 24
PD-(L)1 blockade has made inroads into triple-negative breast cancer, but ER+/Her2- space is still a no go, judging by $MRK flop in Keynote-B49. From #Esmo26 via @ApexOnco -> apexonco.com/esmo-2026-keytr…

ESMO 2026 – Keytruda’s breast cancer flop

Keynote-B49 narrowly scored on PFS, but showed absolutely no benefit on overall survival.

apexonco.com
4
17
4,214
avidresearch retweeted
Lei Lei Wu@leilei_wuuOct 23
BMS has reported a new autoimmune CAR-T death, that it says look unrelated to its ICANS cases or Novartis' IEC-HS deaths that led the companies to pause their trials this summer $BMY My story for @endpts: endpoints.news/bristol-myers…

Bristol Myers reveals autoimmune CAR-T trial death, explains June pause

Bristol Myers Squibb MS patient died post zola-cel CAR-T treatment from septic pneumonia. Company links prior ICANS cases to manufacturing reagent changes, plans trial restart early 2025.

endpoints.news
1
3
1
10
2,302
avidresearch retweeted
Anirban Maitra@Aiims1742Oct 23
Tango reports 82% tumor response rate in trial of combo therapy (Daraxonrasib plus vopimetostat) for advanced #PancreaticCancer at #ESMO26 statnews.com/2026/10/23/esmo… Reduced toxicity data is particularly important as a lower Daraxonrasib dose can be used.

Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer

An experimental drug combination led to tumor responses in 82% of patients with a certain type of advanced pancreatic cancer, Tango Therapeutics reported.

statnews.com
4
53
5
139
13,759
$TNGX did I hear they will try MTAP-Wild type as well ??
1
4
2,417
$TNGX the PFS curve for 2L PDAC is 🔥
A.A
@a_a_freeOct 23
$TNGX data is out : 1- 82% ORR 2- 88.4% 6mo and 9mo landmark PFS (from 90% in June) (100% in 2L) 3- Safety similar rates of low Gr rash, stomatitis/mucositis, and diarrhea as previously reported tangotx.com/wp-content/uploa…
3
8
29
4,566
avidresearch retweeted
dough
@semodoughOct 23
$IDYA IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine Carcinomas - Oct 23, 2026 media.ideayabio.com/2026-10-…

IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising...

[auto]

media.ideayabio.com
1
1
7
5,555
$TNGX NSCLC combo also very impressive ORR 80%
1
5
2
22
7,381
Load more